Haiwang Biotech

Shenzhen Haiwang Bioengineering Co., Ltd., commonly known as Haiwang Biotech, is a leading Chinese pharmaceutical conglomerate that integrates research and development, large-scale manufacturing, and extensive commercial distribution. Founded in 1989 and headquartered in Shenzhen, the company operates across the entire healthcare value chain, producing a wide array of chemical drugs, traditional Chinese medicines (TCM), and nutritional supplements. It is particularly recognized for its massive pharmaceutical logistics and distribution network, which is among the largest in China, serving thousands of hospitals and retail outlets. Haiwang Biotech is a publicly traded company on the Shenzhen Stock Exchange and remains a core subsidiary of the Shenzhen Neptunus Group. The company continues to focus on expanding its portfolio in oncology, cardiovascular health, and infectious diseases while modernizing its TCM production capabilities.